| 582 | 19 | 53 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:观察耳尖放血治疗肝阳上亢型后循环缺血性眩晕(PCIV)的临床疗效及对患者血栓前状态的影响。方法:将124例患者按随机数字表法分为对照组与观察组各62例(两组各终止2例)。对照组口服甲磺酸倍他司汀片;观察组在对照组的基础上增加耳尖放血疗法。疗程30 d。治疗前后进行肝阳上亢证证候积分量表和眩晕障碍调查表(DHI)评分,并进行经颅多普勒超声检查,记录左椎动脉(LVA)、右椎动脉(RVA)、基底动脉(BA)平均流速与血管搏动指数(PI);检测治疗前后血栓前状态指标血浆纤维蛋白原(FIB)、D-二聚体(D-D)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)并进行安全性评价。结果:治疗后,两组患者DHI评分和肝阳上亢证证候积分量表评分显著降低,LVA、RVA与BA的平均流速增加,PI、FIB、D-D显著降低(P<0.01),APTT、PT显著升高(P<0.01);组间比较,以上指标差异均有统计学意义(P<0.01)。观察组疗效优于对照组(P<0.01)。结论:耳尖放血治疗肝阳上亢型PCIV患者可以改善其血栓前状态与脑部血流异常状况,增加脑供血量,从而减轻PCIV的相关症状,提高其生活质量,且安全性高。
Abstract:Objective:To observe the clinical efficacy of blood letting at ear apex in the treatment of posterior circulation ischemic vertigo(PCIV) of hyperactivity of liver yang type and its effect on prethrombotic state in patients. Methods:Totally,124 patients were randomly divided into control group and observation group,62 patients in each group(two cases terminated in earch group). Betastine mesylate tablets were taken orally in the control group,and blood letting at ear apex therapy was further administered in the observation group. The treatment course was 30 days. The syndrome score of hyperactivity of liver yang type,score of dizziness handicap inventory(DHI) were recorded and transcranial Doppler ultrasonography were performed before and after treatment to recorded the average flow velocity and pulsatility index(PI) of left vertebral artery(LVA),right vertebral artery(RVA) and basilar artery(BA). Pre thrombotic status indicators such as plasma fibrinogen(FIB),D-dimer(D-D),prothrombin time(PT),and activated partial thromboplastin time(APTT) before and after treatment were measured,and safety was evaluated. Results:After treatment,the DHI scores and the syndrome scores were significantly decreased,the average flow velocity of LVA,RVA and BA increased,PI,FIB and D-D decreased significantly( P < 0.01), and APTT and PT increased significantly in both groups( P < 0.01). The differences in the above indicalors between groups were statistically significant(P<0.05). Comparison between groups showed that the efficacy in the observation group was better than that in the control group(P<0.01). Conclusions:Blood letting at ear apex can improve the prethrombotic state and abnormal cerebral blood flow in PCIV patients of hyperactivity of liver yang type,increase the cerebral blood supply,so as to reduce the related symptoms of PCIV and improve life quality of patients,and with high security.
[1]中华医学会神经病学会,中华神经科杂志编辑委员会.眩晕诊治多学科专家共识[J].中华神经科杂志,2017,50(11):805-812.
[2]程芳丽,潘卫,李永杰,等.经皮穴位电刺激治疗后循环缺血疗效和脑血循环动力学研究[J].中国实用内科杂志,2009,29(1):53-55.
[3]於芸,姜文,石海卫,等.自拟强力止晕汤治疗肝阳上亢兼痰湿中阻型后循环缺血性眩晕对TCD、BAEP的影响及远期预后评价[J].中药材,2022,45(2):467-471.
[4]傅颖颖.耳尖放血治疗肝阳上亢证高血压临床效果研究[J].中国全科医学,2021,24(S2):188-190.
[5]中国后循环缺血专家共识组.中国后循环缺血的专家共识[J].中华内科杂志,2006,45(9):786-787.
[6]中华人民共和国卫生部.中药新药临床研究指导原则(第一辑)[M].北京:人民卫生出版社,1993:24-25.
[7]刘爱华,张婉莹,龚凌云,等.建瓴汤对改善后循环缺血性眩晕患者椎动脉血流的临床观察[J].世界中西医结合杂志,2018,13(3):305-309.
[8]张炜,贾国章,杨斌,等.后循环缺血性孤立性眩晕临床研究现状[J].临床误诊误治,2019,32(5):113-116.
[9] LI L,HE S,LIU H,et al. Potential risk factors of persistent postural-perceptual dizziness:a pilot study[J]. J Neurol,2022,269(6):3075-3085.
[10] WANG Y,ZHOU X,LUO Y. Predicting value of fibrinogen in identifying cerebrovascular ischemic events in patients with dizziness/vertigo[J]. Neurol Sci,2022,43(2):1105-1113.
[11] JO S,JEONG T,LEE J B,et al. Incidence of acute cerebral infarction or space occupying lesion among patients with isolated dizziness and the role of D-dimer[J]. PLoS One,2019,14(3):e214661.
[12]郭文苹,屈永涛,郭明丽,等.全聋伴眩晕的突发性聋患者凝血状态分析[J].临床耳鼻咽喉头颈外科杂志,2022,36(3):172-176.
[13]陈华德,方针,王翀敏.耳尖放血治疗高血压病肝阳上亢证疗效观察[J].中国针灸,2004,24(4):9-11.
[14]方跃屏,吴如飞,朱政铭,等.耳尖放血治疗肝阳上亢证高血压病98例[J].浙江中医杂志,2017,52(11):838.
[15]吕金丹.耳尖放血合散偏汤治疗肝阳上亢型普通型偏头痛临床研究[J].湖北中医杂志,2014,36(12):6-7.
[16]王凤蕊,汤国娟,叶玲.陈华德教授针灸治疗肝阳上亢型眩晕的临床经验[J].浙江中医药大学学报,2016,40(7):560-561.
[17]张美林.天麻钩藤饮加减煎服联合耳尖放血疗法治疗肝阳上亢型顽固性高血压30例[J].中医外治杂志,2017,26(3):26-27.
基本信息:
DOI:10.16295/j.cnki.0257-358x.2023.12.009
中图分类号:R255.3
引用信息:
[1]董蓉洁,石蓬莱.耳尖放血治疗肝阳上亢型后循环缺血性眩晕临床研究[J].山东中医杂志,2023,42(12):1295-1300.DOI:10.16295/j.cnki.0257-358x.2023.12.009.
基金信息:
山东省中医药科技计划项目(编号:2020Q090)
2023-12-05
2023-12-05